UroToday

SUO 2025: Efficacy of Rucaparib vs Physician’s Choice in Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer by Age: Results from the TRITON3 Study

SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.
UroToday

ESMO 2025: IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

(UroToday.com) The 2025 ESMO annual meeting featured a Presidential Symposium session and a presentation by Dr. Thomas B. Powles discussing results from IMvigor011, a phase 3 trial of ctDNA-guided ...
UroToday

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...
UroToday

Non-Muscle Invasive Bladder Cancer

EAU 2025, non-muscle invasive bladder cancer (NMIBC), DaBlaCa-15 Trial, Xpert® Bladder Cancer, Urinary Biomarker Test Xpert® Bladder Cancer Monitor for Guiding Cystoscopy, High-grade ...
UroToday

ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations ...

San Francisco, California (UroToday.com) The PROfound Study is the first positive randomized Phase 3 study in a molecularly-defined population of patients with metastatic castration-resistant prostate ...
UroToday

SUO 2025: Trials in Progress - CONSOLIdaTE-01: Phase II Trial of Consolidative Surgery Following Enfortumab Vedotin + Pembrolizumab in Patients with Locally Advanced ...

(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Fady Ghali discussing CONSOLIdaTE-01, a phase II trial of consolidative ...
UroToday

ESMO 2025: Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a Phase II Trial of a Novel RNAseq-based ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany, between October 17 th and 21 st, 2025, was host to a renal and urothelial carcinoma ...
UroToday

ESMO 2025: Neoadjuvant Darolutamide + ADT for High/very-High Risk Locally Advanced Prostate Cancer: A Multi-Center, Open Label, Single Arm, Phase 2 Trial

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Kaiwei Yang discussing a phase 2 trial assessing neoadjuvant darolutamide + ADT for ...